DaVita Inc
DVA: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$926.00 | Wxbvdgf | Rqlzsfbt |
DaVita Earnings: Higher Revenue Per Treatment Helps Boost 2024 Outlook and Fair Value
Narrow-moat DaVita turned in solid second-quarter results, and management bumped up its bottom-line expectations slightly. To reflect those mildly higher near-term expectations and recent cash flows, we are raising our fair value estimate on DaVita to $134 per share from $122.